| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
MWCL-1 was established as LPL cell line. MWCL-1 cells were classified into three subpopulations using a flow cytometer with anti-CD20 and anti-CD138 antibodies: CD20－CD138－, CD20＋CD138－, and CD20＋CD138＋. When cultured, CD20－CD138－ cells yielded all three subpopulations. Compared to the other subpopulations, CD20－CD138－ cells possessed the efficient ROS expelling and in vitro colony formation activities, and were resistant to apoptosis. These results suggested that CD20－CD138－ cells might be a candidate for tumor-initiating cells in LPL. Low oxygen culture of MWCL-1 induced the production of CD20－CD138－ cells, and this result suggested that hypoxia was an advantageous microenvironment for CD20－CD138－ cells. CXCR7 mRNA/protein expression was the highest in CD20－CD138－ cells. When CXCL12, a ligand of CXCR7, was added, the proportion of CD20－CD138－ cells significantly increased. CXCL12-CXCR7 signaling might exert a great influence on CD20－CD138－ cells.
|
